Our Trials

Haematology Clinical Trial Unit - Current trials open to recruitment

For more information Please contact:
Lisa Demosthenous
Haematology Clinical Trial Unit Manager
Lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182

A/Prof Constantine (Con) Tam, MBBS, MD, FRACP, FRCPA
Director of Haematology
constantine.tam@svha.org.au

Dr Hang Quach MBBS (Hons) SpecCertOC FRACP FRCPA MD
Consultant Clinical and Laboratory Haematologist
hang.quach@svha.org.au

 

AMaRC 03-16 VCDD vs VCD | A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
 
NBCR | Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)
 
Best Bat | A Multi-Centred Study Validating a Bleeding Assessment Tool (BAT) Developed by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative For Use in Adult Patients with Haematological Malignancy
 
BGB311_AU_003 (monotherapy) | A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies
 
BGB3111_212 (FL) | An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
 
BGB3111_304 (TN CLL) | An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
 
BGB3111_WM_302 (Waldenstrom's) | A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobulinemia (WM)
 
COLUMBA S/C DARA MMY3012 (RRMM) | A Phase 3 Study Of Subcutaneous Vs. Intravenous Administration Of Daratumumab In Relapsed Or Refractory Multiple Myeloma
 
Hutchison 2015-523-00AU1 | A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics ofHMPL-523 in patients with relapsed or refractory Hematologic Malignancies
 
IKEMA EFC15246 (RRMM 1-3 lines) | Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapse and/or refractory multiple myeloma previously treated with 1 to 3 prior lines
 
KappaMab (HLX-KM-03) | A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma
 
Karyopharm (KCP-330-023) Selinexor (BOSTON) | A Phase 3 Randomized, Controlled, Open-Label Study Of Selinexor, Bortezomib, And Dexamethasone (Svd) Versus Bortezomib And Dexamethasone (Vd) In Patients With Relapsed Or Refractory Multiple Myeloma (RRMM)
 
M15-522 - MDS (Venetoclax/Aza) | A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as a Single-Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure
 
M15-656 - AML (Venetoclax/Aza) | A randomized, double-blinded, placebo controlled, phase 3, multicenter, study comparing Venetoclax in combination with Azacitidine Versus Placebo in combination with Azacitidine in Treatment Naïve subjects with Acute Myeloid Leukemia who are ≥ 65 years of age and ineligible for Standard Induction Therapy.
 
Millenium C16021 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
 
MK3475-155 | Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)
 
MK3475-204 | A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
 
MM17 | A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy
 
MM18 | Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM)
 
Myeloma 1000 Registry | The Myeloma 1000 Project 
 
NHL29 | IRiC trial: a Phase II study of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL. 
 
PCYC1142 | Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma
 
PCYC1143 | Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
 
ROCHE NP39403 (BET Inhibitor) | Open-Label, Multicenter, Dose-Escalation/Expansion Phase Ib Study To Evaluate Safety, Pharmacokinetics, And Activity Of Bet Inhibitor Ro6870810, Given As Mono- And Combination Therapy To Patients With Advanced Multiple Myeloma
 
Takeda C16029 (RRMM) | A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)
 
TREATT | TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia. A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe thrombocytopenia.